TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab
Brief Summary: The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with relapsed or refractory CLL. Participants will be randomly assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine + rituximab (Arm B).


Options:
A: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide
B: Arm Label: Bendamustine + Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Venetoclax + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Arm Label: Bendamustine + Rituximab Crossover Substudy; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Arm Label: Venetoclax + Rituximab Re-Treatment; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Bendamustine + Rituximab Crossover Substudy, Venetoclax + Rituximab, Venetoclax + Rituximab Re-Treatment | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Bendamustine + Rituximab, Bendamustine + Rituximab Crossover Substudy, Venetoclax + Rituximab, Venetoclax + Rituximab Re-Treatment
C: Arm Label: Bendamustine + GA101 + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib
D: Arm Label: Arm A (CLL/SLL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Arm Label: Arm B (NHL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Intervention Type: DRUG; Name: ABT-199; Assigned to Arm(s): Arm A (CLL/SLL subjects), Arm B (NHL subjects)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Phase II, Single-centre Study to Assess the Safety and Efficacy of Silymarin 700 mg Capsules TID for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Brief Summary: This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver. The study hypothesis is that high dose Sillymarin will be able to reduce steato-hepatitis (fat-related liver inflammation) better than placebo.


Options:
A: Arm Label: Lepicol probiotic & prebiotic formula+simple lifestyle advice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepicol probiotic & prebiotic formula, Other: Simple lifestyle advice | Arm Label: Simple lifestyle advice alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Simple lifestyle advice | Intervention Type: DRUG; Name: Lepicol probiotic & prebiotic formula; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice | Intervention Type: OTHER; Name: Simple lifestyle advice; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice, Simple lifestyle advice alone
B: Arm Label: Sillymarin; Type: EXPERIMENTAL; Interventions: Drug: Sillymarin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sillymarin; Assigned to Arm(s): Sillymarin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ginseng trial; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Red ginseng | Intervention Type: DIETARY_SUPPLEMENT; Name: Red ginseng; Assigned to Arm(s): Ginseng trial
D: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Primary Motor Cortex and Prefrontal Cortex for Facilitation of Motor System and Working Memory in Stroke, Parkinson, and Elderly Patients
Brief Summary: The investigators hypothesize that ten sessions of repetitive transcranial magnetic stimulation yield ability to upregulate the function of primary motor cortex and prefrontal cortex that play key roles in motor and frontal memory processing.


Options:
A: Arm Label: Intensive group; Type: EXPERIMENTAL; Interventions: Procedure: Cognitive rehabilitation | Arm Label: Conventional group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive rehabilitation | Intervention Type: PROCEDURE; Name: Cognitive rehabilitation; Assigned to Arm(s): Conventional group, Intensive group
B: Arm Label: Prism adaptation treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Prism Goggles | Arm Label: Sham prism adaptation treatment; Type: SHAM_COMPARATOR; Interventions: Other: Non-Shifting Goggles | Intervention Type: BEHAVIORAL; Name: Prism Goggles; Assigned to Arm(s): Prism adaptation treatment | Intervention Type: OTHER; Name: Non-Shifting Goggles; Assigned to Arm(s): Sham prism adaptation treatment
C: Arm Label: High frequency rTMS plus fNIRS; Type: EXPERIMENTAL; Interventions: Device: Functional near infrared spectroscopy, Device: rTMS | Arm Label: Sham rTMS; Type: SHAM_COMPARATOR; Interventions: Device: rTMS | Arm Label: High frequency rTMS; Type: EXPERIMENTAL; Interventions: Device: rTMS | Intervention Type: DEVICE; Name: Functional near infrared spectroscopy; Assigned to Arm(s): High frequency rTMS plus fNIRS | Intervention Type: DEVICE; Name: rTMS; Assigned to Arm(s): High frequency rTMS, High frequency rTMS plus fNIRS, Sham rTMS
D: Arm Label: sensorimotor therapy; Type: EXPERIMENTAL; Interventions: Other: additional sensorimotor therapy for the upper limb | Arm Label: motor therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: additional motor therapy for the upper limb after stroke | Intervention Type: OTHER; Name: additional sensorimotor therapy for the upper limb; Assigned to Arm(s): sensorimotor therapy | Intervention Type: OTHER; Name: additional motor therapy for the upper limb after stroke; Assigned to Arm(s): motor therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in patients with COPD.


Options:
A: Arm Label: FF MDI (PT005); Type: EXPERIMENTAL; Interventions: Drug: FF MDI (PT005) | Arm Label: GP MDI (PT001); Type: EXPERIMENTAL; Interventions: Drug: GP MDI (PT001) | Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) | Arm Label: Placebo MDI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GFF MDI (PT003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: GP MDI (PT001); Assigned to Arm(s): GP MDI (PT001) | Intervention Type: DRUG; Name: FF MDI (PT005); Assigned to Arm(s): FF MDI (PT005) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI
B: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
C: Arm Label: tiotropium + olodaterol low dose; Type: EXPERIMENTAL; Interventions: Drug: olodaterol, Drug: tiotropium | Arm Label: tiotropium + olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: olodaterol, Drug: tiotropium | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol high dose, tiotropium + olodaterol low dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium, tiotropium + olodaterol high dose, tiotropium + olodaterol low dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aclidinium Bromide | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Drug Reconciliation at Discharge and Pharmaceutical Communication Between Hospital and Community Pharmacists on Drug Related Problems: Study Protocol for a Cluster Randomized Cross-over Trial
Brief Summary: This study will evaluate the impact of a communication between hospital pharmacist and community pharmacists in addition to drugs reconciliation procedure at discharge. It will be conducted in 21 french public hospitals.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Link2Care; Type: EXPERIMENTAL; Interventions: Other: Link2Care | Intervention Type: OTHER; Name: Link2Care; Assigned to Arm(s): Link2Care
B: Arm Label: Re-engineered hospital discharge; Type: EXPERIMENTAL; Interventions: Behavioral: Re-Engineered Hospital Discharge | Arm Label: Standard hospital discharge; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Re-Engineered Hospital Discharge; Assigned to Arm(s): Re-engineered hospital discharge
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: reconciliation | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: reconciliation; Assigned to Arm(s): intervention
D: Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal intervention | Arm Label: Enhanced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Minimal intervention; Assigned to Arm(s): Minimal intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections
Brief Summary: The purpose of this study is to determine, in patients who undergo an elective colorectal resection through a midline laparotomy incision, whether the use of negative pressure wound therapy (NPWT) applied to the site of the laparotomy compared to standard care alone, reduces the incidence of surgical site infection (SSI) in the first 30 days postoperatively. The investigators hypothesize that the use of NPWT will reduce the rate of postoperative SSI, as well as decrease the need for Nursing Home Care for SSI, length of hospital stay and return visits related to SSI.


Options:
A: Arm Label: Closed Incision Wound vacuum (Prevena); Type: EXPERIMENTAL; Interventions: Device: Closed incision wound vacuum (Prevena) | Arm Label: Routine Wound Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Closed incision wound vacuum (Prevena); Assigned to Arm(s): Closed Incision Wound vacuum (Prevena)
B: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative Pressure Wound Therapy, Other: Usual Care of Surgical Wound | Arm Label: Usual Care of Surgical Wound; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care of Surgical Wound | Intervention Type: DEVICE; Name: Negative Pressure Wound Therapy; Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: OTHER; Name: Usual Care of Surgical Wound; Assigned to Arm(s): Negative Pressure Wound Therapy, Usual Care of Surgical Wound
C: Arm Label: Negative pressure dressing; Type: EXPERIMENTAL; Interventions: Device: Negative pressure dressing | Arm Label: Standard dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard wound dressing | Intervention Type: DEVICE; Name: Negative pressure dressing; Assigned to Arm(s): Negative pressure dressing | Intervention Type: DEVICE; Name: Standard wound dressing; Assigned to Arm(s): Standard dressing
D: Arm Label: High Risk - Prevena Care; Type: EXPERIMENTAL; Interventions: Device: Prevena Care | Arm Label: High Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Arm Label: Low Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Intervention Type: DEVICE; Name: Prevena Care; Assigned to Arm(s): High Risk - Prevena Care | Intervention Type: DEVICE; Name: Dry gauze dressing care; Assigned to Arm(s): High Risk - Dry Gauze Dressing Care, Low Risk - Dry Gauze Dressing Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections
Brief Summary: The purpose of this study is to determine, in patients who undergo an elective colorectal resection through a midline laparotomy incision, whether the use of negative pressure wound therapy (NPWT) applied to the site of the laparotomy compared to standard care alone, reduces the incidence of surgical site infection (SSI) in the first 30 days postoperatively. The investigators hypothesize that the use of NPWT will reduce the rate of postoperative SSI, as well as decrease the need for Nursing Home Care for SSI, length of hospital stay and return visits related to SSI.


Options:
A: Arm Label: Negative pressure dressing; Type: EXPERIMENTAL; Interventions: Device: Negative pressure dressing | Arm Label: Standard dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard wound dressing | Intervention Type: DEVICE; Name: Negative pressure dressing; Assigned to Arm(s): Negative pressure dressing | Intervention Type: DEVICE; Name: Standard wound dressing; Assigned to Arm(s): Standard dressing
B: Arm Label: Prevena device (Group A); Type: EXPERIMENTAL; Interventions: Device: Prevena device (Group A) | Arm Label: Conventional dressing (Group B); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Prevena device (Group A); Assigned to Arm(s): Prevena device (Group A)
C: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative Pressure Wound Therapy, Other: Usual Care of Surgical Wound | Arm Label: Usual Care of Surgical Wound; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care of Surgical Wound | Intervention Type: DEVICE; Name: Negative Pressure Wound Therapy; Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: OTHER; Name: Usual Care of Surgical Wound; Assigned to Arm(s): Negative Pressure Wound Therapy, Usual Care of Surgical Wound
D: Arm Label: Vacuum assisted closure; Type: EXPERIMENTAL; Interventions: Procedure: vacuum assisted closure | Arm Label: Axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary dissection | Intervention Type: PROCEDURE; Name: vacuum assisted closure; Assigned to Arm(s): Vacuum assisted closure | Intervention Type: PROCEDURE; Name: Axillary dissection; Assigned to Arm(s): Axillary dissection

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections
Brief Summary: The purpose of this study is to determine, in patients who undergo an elective colorectal resection through a midline laparotomy incision, whether the use of negative pressure wound therapy (NPWT) applied to the site of the laparotomy compared to standard care alone, reduces the incidence of surgical site infection (SSI) in the first 30 days postoperatively. The investigators hypothesize that the use of NPWT will reduce the rate of postoperative SSI, as well as decrease the need for Nursing Home Care for SSI, length of hospital stay and return visits related to SSI.


Options:
A: Arm Label: Standard wound dressing OPEN; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PICO dressing OPEN; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy with PICO (Smith & Nephew) | Arm Label: Standard dressing EVAR; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PICO dressing EVAR; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy with PICO (Smith & Nephew) | Intervention Type: DEVICE; Name: Negative pressure wound therapy with PICO (Smith & Nephew); Assigned to Arm(s): PICO dressing EVAR, PICO dressing OPEN
B: Arm Label: Prophylactic NPWT; Type: EXPERIMENTAL; Interventions: Device: Prophylactic NPWT | Arm Label: Standard Dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard Dressing | Intervention Type: DEVICE; Name: Prophylactic NPWT; Assigned to Arm(s): Prophylactic NPWT | Intervention Type: DEVICE; Name: Standard Dressing; Assigned to Arm(s): Standard Dressing
C: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative Pressure Wound Therapy, Other: Usual Care of Surgical Wound | Arm Label: Usual Care of Surgical Wound; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care of Surgical Wound | Intervention Type: DEVICE; Name: Negative Pressure Wound Therapy; Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: OTHER; Name: Usual Care of Surgical Wound; Assigned to Arm(s): Negative Pressure Wound Therapy, Usual Care of Surgical Wound
D: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Shifting Sedentary Behaviors to Light Activities on Energy Expenditure: A Randomized Controlled Trial in Sedentary Adults
Brief Summary: The main purposes of this randomized cross-over trial are to test if a 3h/day reduction of time spent in sedentary behaviour (SB) through breaking up hourly and shifting it for standing and walking behaviours would substantially increase total (TEE) and PA energy expenditure (PAEE) compared to a week of habitual prolonged SB, in male and female overweight/obese inactive (which do not attained MVPA recommendations) and sedentary desk workers. Specifically using an experiment design our main aims are: a) to determine the impact of reducing SB on TEE and PAEE; b) to analyse the independent effects of interrupting SB through breaks and the overall reduction in SB on TEE and PAEE; c) To analyse the determinants for the overall reduction in SB; d) If the changes occurred in TEE and PAEE were dependent on specific covariates.


Options:
A: Arm Label: Lifestyle change; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sedentary time by breaking it with low intensity physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sedentary time by breaking it with low intensity physical activity; Assigned to Arm(s): Lifestyle change
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Theoretical & practical exercise counseling | Intervention Type: BEHAVIORAL; Name: Theoretical & practical exercise counseling; Assigned to Arm(s): Exercise
C: Arm Label: Motivational lifestyle counselling; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Lifestyle Counselling | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Lifestyle Counselling; Assigned to Arm(s): Motivational lifestyle counselling
D: Arm Label: I-STAND; Type: EXPERIMENTAL; Interventions: Behavioral: I-STAND | Arm Label: Healthy Living; Type: ACTIVE_COMPARATOR; Interventions: Other: Healthy Living | Intervention Type: BEHAVIORAL; Name: I-STAND; Assigned to Arm(s): I-STAND | Intervention Type: OTHER; Name: Healthy Living; Assigned to Arm(s): Healthy Living

Answer: A